Phase 3 Recruiting Academic/Other
This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monocl…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in Georgia: - Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
- Augusta University Medical Center — Augusta, Georgia
Phase 3 Recruiting Network
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…
Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in Georgia: - Children's Healthcare of Atlanta - Arthur M Blank Hospital — Atlanta, Georgia
- Augusta University Medical Center — Augusta, Georgia
- Atrium Health Navicent — Macon, Georgia
- Memorial Health University Medical Center — Savannah, Georgia
Phase 3 Recruiting Network
This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs …
Sponsor: Children's Oncology Group
NCT ID: NCT04293562
Sites in Georgia: - Children's Healthcare of Atlanta - Arthur M Blank Hospital — Atlanta, Georgia
- Augusta University Medical Center — Augusta, Georgia
- Memorial Health University Medical Center — Savannah, Georgia
Phase 3 Recruiting Industry
Study comparing efficacy and safety of olverembatinib (investigational arm) vs. bosutinib (control arm) in patients with CML-CP (Part A). Study will also evaluate efficacy and safety of olverembatinib (single-arm) in CML-CP patients with T…
Sponsor: Ascentage Pharma Group Inc.
NCT ID: NCT06423911
Sites in Georgia: - Ascentage Investigative Site #1045 — Augusta, Georgia
- Ascentage Investigative Site #1110 — Newnan, Georgia
Phase 2, Phase 3 Recruiting Academic/Other
This screening and multi-sub-study Phase 1b/2/3 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloi…
Sponsor: Beat AML, LLC
NCT ID: NCT03013998
Sites in Georgia: - Winship Cancer Institute of Emory University — Atlanta, Georgia
- Georgia Cancer Center — Augusta, Georgia
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia a…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317649
Sites in Georgia: - Phoebe Putney Memorial Hospital — Albany, Georgia
- Augusta University Medical Center — Augusta, Georgia
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML)…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554406
Sites in Georgia: - Phoebe Putney Memorial Hospital — Albany, Georgia
- Augusta University Medical Center — Augusta, Georgia
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554393
Sites in Georgia: - Phoebe Putney Memorial Hospital — Albany, Georgia
Phase 1, Phase 2 Recruiting Academic/Other
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…
Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in Georgia: - Children's Healthcare of Atlanta - Arthur M Blank Hospital — Atlanta, Georgia
- Memorial Health University Medical Center — Savannah, Georgia
Phase 2 Recruiting NIH
This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-li…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06124157
Sites in Georgia: - Children's Healthcare of Atlanta - Arthur M Blank Hospital — Atlanta, Georgia
- Augusta University Medical Center — Augusta, Georgia
- Atrium Health Navicent — Macon, Georgia
- Memorial Health University Medical Center — Savannah, Georgia
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Georgia: - Children's Healthcare of Atlanta - Arthur M Blank Hospital — Atlanta, Georgia
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 4 indication-specific expansion coho…
Sponsor: Syndax Pharmaceuticals
NCT ID: NCT04065399
Sites in Georgia: - Emory Winship Cancer Institute — Atlanta, Georgia
- Children's Healthcare of Atlanta — Atlanta, Georgia
Phase 1, Phase 2 Recruiting Academic/Other
This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-…
Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
NCT ID: NCT05849662
Sites in Georgia: - Children's Hospital of Atlanta — Atlanta, Georgia
Phase 1, Phase 2 Recruiting Industry
SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation groups (Group 1 in patients with relapsed/r…
Sponsor: Sellas Life Sciences Group
NCT ID: NCT04588922
Sites in Georgia: - City of Hope - Atlanta — Newnan, Georgia
Phase 2 Recruiting Industry
The primary objectives of this study are to assess: (1) whether the combination of BP1001 plus venetoclax plus decitabine provides greater efficacy (Complete Remission \[CR\], Complete Remission with incomplete hematologic recovery \[CRi\]…
Sponsor: Bio-Path Holdings, Inc.
NCT ID: NCT02781883
Sites in Georgia: - Georgia Cancer Center at Augusta University — Augusta, Georgia
Phase 2 Recruiting Academic/Other
This is a Phase 2 study of the study drug, ivosidenib (a mutant IDH1 inhibitor), compared to placebo, given to patients with IDH1-mutant acute myeloid leukemia (AML) after hematopoietic stem cell transplantation (HCT).
Sponsor: Massachusetts General Hospital
NCT ID: NCT06707493
Sites in Georgia: - Emory University Hospital — Atlanta, Georgia
Phase 2 Recruiting Academic/Other
This phase II trial tests the effect of venetoclax and obinutuzumab followed by epcoritamab in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that have not previously received treatment. Venet…
Sponsor: City of Hope Medical Center
NCT ID: NCT07218510
Sites in Georgia: - City of Hope Atlanta Cancer Center — Newnan, Georgia
Phase 1, Phase 2 Recruiting Industry
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
Sponsor: CellCentric Ltd.
NCT ID: NCT04068597
Sites in Georgia: - Emory Winship Cancer Institute — Atlanta, Georgia
Phase 2 Recruiting Academic/Other
Changing the schedule of intrathecal chemotherapy to be given before and during blinatumomab will maintain the anti-leukemic effects of this drug while at the same time adding the benefit of limiting the neurotoxicity associated with cytok…
Sponsor: Northside Hospital, Inc.
NCT ID: NCT05519579
Sites in Georgia: - Northside Hospital — Atlanta, Georgia
Phase 1 Recruiting Industry
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose c…
Sponsor: Kura Oncology, Inc.
NCT ID: NCT06001788
Sites in Georgia: - Emory Healthcare - The Emory Clinic — Atlanta, Georgia
- Georgia Cancer Center at Augusta University — Augusta, Georgia
Phase 1 Recruiting Network
This phase I trial tests the safety, side effects, and best dose of imetelstat in combination with fludarabine and cytarabine in treating patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or juvenile myelomonocytic…
Sponsor: Children's Oncology Group
NCT ID: NCT06247787
Sites in Georgia: - Children's Healthcare of Atlanta - Arthur M Blank Hospital — Atlanta, Georgia
Phase 1 Recruiting NIH
This phase I trial studies the side effects and best dose of lenalidomide when given together with usual combination chemotherapy (etoposide, prednisone, vincristine sulfate \[Oncovin\], cyclophosphamide, and doxorubicin hydrochloride \[hy…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04301076
Sites in Georgia: - Emory University Hospital Midtown — Atlanta, Georgia
- Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
Phase 1 Recruiting Industry
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.
Sponsor: Nurix Therapeutics, Inc.
NCT ID: NCT05131022
Sites in Georgia: - Winship Cancer Institute of Emory University — Atlanta, Georgia
Phase 1 Recruiting Industry
This is a clinical study aiming to assess pharmacokinetics, pharmacodynamics and preliminary efficacy of ZE46-0134 in patients with FLT3 and spliceosome mutated Relapsed or Refractory Acute Myeloid Leukemia
Sponsor: Lomond Therapeutics Holdings, Inc.
NCT ID: NCT06366789
Sites in Georgia: - Emory University — Atlanta, Georgia
Phase 1 Recruiting Industry
This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL, r/r B-cell N…
Sponsor: Imugene Limited
NCT ID: NCT03666000
Sites in Georgia: - Winship Cancer Institute Emory University — Atlanta, Georgia
- Northside Hospital Cancer Institute — Atlanta, Georgia